Genome editing company Editas Medicine has set the terms for its upcoming IPO, set to raise around $100 million in capital. The company plans to offer 5.9 million shares within a price range of $16 to $18 each. Shares will list on the NASDAQ under the symbol EDIT. The company has raised a total of $163 million in funding, most recently securing a $120 million round in August at a valuation of $379 million. Investors in the company include Flagship Ventures (16.6% pre-IPO stake), Polaris Partners (15.6%) and Third Rock Ventures (15.6%). Editas plans to use approximately $15 million to $20 million of the net proceeds from the offering for preclinical studies and clinical trials of its treatment for a form of retinal degeneration.